8-K
filed January 29, 2026, 6:59 PM ET
ticker APRE
CIK 0001781983
other material
confidence high
sentiment positive
materiality 0.75
Aprea reports first partial response for APR-1051; raises $5.6M in private placement
Aprea Therapeutics, Inc.
- First unconfirmed partial response (uPR) in PPP2R1A-mutated endometrial cancer at 150 mg: 50% target lesion reduction, CA-125 from 732 to 70 U/mL.
- Stable disease at 70 mg (HNSCC, 5% reduction) and 100 mg (colon cancer, 15% reduction; >210 days on therapy).
- Private placement ~$5.6M gross: 6.3M shares/pre-funded warrants + 6.3M warrants at $0.765; priced $0.89/unit. Closes Jan 30, 2026.
- Dose escalation continues; 220 mg cohort enrolling; company plans to increase HPV-positive enrollment.
- Potential dose-response trend observed across 70 mg, 100 mg, and 150 mg cohorts.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Aprea Therapeutics, Inc. issued warrant to certain accredited investors for $0.89 per unit (combined with share or warrant).
- Security
- warrant
- Purchaser
- certain accredited investors
- Consideration
- $0.89 per unit (combined with share or warrant)
Exact text from the filing
Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds at closing of approximately $5.6 million. The closing of
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Aprea Therapeutics, Inc. issued up to 6,288,857 shares of Common Stock of warrant to certain accredited investors for $0.89 per unit (combined with share or warrant).
- Security
- warrant
- Shares
- up to 6,288,857 shares of Common Stock
- Purchaser
- certain accredited investors
- Consideration
- $0.89 per unit (combined with share or warrant)
Exact text from the filing
Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds at closing of approximately $5.6 million. The closing of
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Aprea Therapeutics, Inc. issued 6,288,857 shares of common stock to certain accredited investors for $0.89 per unit (combined with warrant).
- Security
- common stock
- Shares
- 6,288,857 shares
- Purchaser
- certain accredited investors
- Consideration
- $0.89 per unit (combined with warrant)
Exact text from the filing
Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds at closing of approximately $5.6 million. The closing of
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors (the Purchasers) valued at expected aggregate gross proceeds at closing of approximately $5.6 million (effective 2026-01-28).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors (the Purchasers)
- Value
- expected aggregate gross proceeds at closing of approximately $5.6 million
- Effective
- 2026-01-28
Exact text from the filing
On January 28, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 6,288,857 shares (the “ Private Placement Shares ”) of the Company’s Common Stock, par value $0.001 per share (“ Common Stock ”) or pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) in lieu thereof, and (ii) common stock purchase warrants to purchase up to 6,288,857 shares of Common Stock (the “ Warrant Shares ”) at an exercise price of $0.765 per share (the “ Common Warrants ” and together with the Pre-Funded Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Aprea Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Purchasers valued at customary indemnification rights (effective 2026-01-29).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Company and the Purchasers
- Value
- customary indemnification rights
- Effective
- 2026-01-29
Exact text from the filing
In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated January 29, 2026 (the “ Registration Rights Agreement ”), providing for the registration for resale of Private Placement Shares along with the shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants that are not then registered on an effective registration statement, pursuant to a registration statement (the “ Registration Statement ”) to be filed with the Securities and Exchange Commission (the “ SEC ”) on or prior to the 60 th day after the Closing Date.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.